FDA Inspection
BloodworksBloodworks – FDA Inspection, Aug 17, 2017
Record Details
This FDA Inspection record concerns Bloodworks, with an inspection on August 17, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · f6dc58dd-871b-498f-b463-2c2782ca0215
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1023273
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
- Outcome
- Form 483 issued
Other FDA inspections of Bloodworks
15| Date | Classification | Office | Project area |
|---|---|---|---|
| December 11, 2025 | Not classified | Seattle District Office | Blood and Blood Products |
| May 3, 2024 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| July 16, 2021 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| April 18, 2019 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| June 7, 2018 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Bloodworks
- FDA Inspection 1294906 - 2025-12-11
- FDA Inspection 1238690 - 2024-05-03
- FDA Inspection 1146276 - 2021-07-16
- FDA Inspection 1087821 - 2019-04-18
- FDA Inspection 1056331 - 2018-06-07
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.